Skip to main content

AVV9-minidystrophin (Pfizer- PF-06939926) for Duchenne Muscular Dystrophy: Clinical Study Update

AVV9-minidystrophin (Pfizer- PF-06939926) for Duchenne Muscular Dystrophy 

Clinical Stage and Regulatory Timeline

PF-06939926 is an investigational gene transfer therapy intended to deliver its mini-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.(AAV9.Muscle-promoter.micro-dystrophin). Pfizer is initiating phase 3 pivotal trial to determine safety, efficacy of the PF-06939926 with 3e14 vg/kg dose.

Viral Vector and Gene Construct

AAV9.MuscleProtomter.mini-dystrophin (3.9Kb), The propriety muscle promoter drives the expression of the minidystrophin gene in the muscle tissue. AAV9 have shown to have high tropism for skeletal and cardiac muscle. 

Clinical Phase

Pfizer is currently conducting a Phase 3 (NCT04281485) randomized, double-blind, placebo-controlled study to safety and efficacy of the exogenous gene transfer in DMD subjects. The Phase 1b study conducted to determine the safety and tolerability of the AAV9.Muscle-promoter.micro-dystrophin is completed and one year data is provided in the ASGCT Investor call. 

Number of Participants in Phase 3 Study- 99

Outcome Measures

Primary Outcome Measures

  • Change from Baseline in North Star Ambulatory Assessment (NSAA) at 52 weeks

Secondary Outcome Measures
  • Change from Baseline in mini-dystrophin expression level in muscle up to 52 weeks
  • Quantification of Mini-dystrophin expression level from a muscle biopsy using by liquid chromatography mass spectrometry (LC-MS).Change from Baseline in distribution of mini-dystrophin expression in the muscle
  • Mini-dystrophin distribution from a muscle biopsy will be assessed by immunofluorescence
  • Change from Baseline in serum creatine kinase (CK)

 Key Results from Phase 1b

A single dose of 1.0e14 vg/kg or 3.0 e14 vg/kg AAV9.MuscleProtomter.mini-dystrophin was infused through a peripheral limb vein. Dose-dependent increase in mini-dystrophin expression was observed, and high dose 3.0 e14 vg/kg showed the efficacy and tolerability.  

Efficacy 
In the high-dose cohort (n=3) for whom 12-month data are available, the mean percent normal dystrophin at 12 months was 51.6% mean normal dystrophin level. Significant and Sustained Distribution of Dystrophin in muscle biopsy were observed by immunofluorescence

All clinical subject (both low does and high dose patient) showed a significant functional improvement from baseline NSAA scores after one year, compared with the scores in an independent, external control group. 

Durability (Up to 2 years):

Improved NSAA Total Score By Age at Time of Assessment 1 Years The increases in dystrophin levels observed at 2 months were generally sustained at 12 months, and 5 of the 6 boys showed an increase in mini-dystrophin concentration between the 2- and 12-month time points.


Safety:

Serious Adverse Events: Three SAE were observed.

  • Persistent vomiting resulting in dehydration (required admission for IV anti-emetics and fluids)
  • Acute kidney injury with atypical hemolytic uremic syndrome (aHUS)-like complement activation (required hemodialysis and eculizumab)
  • Thrombocytopenia with aHUS-like complement activation (required platelet transfusion and eculizumab)

Immunogenicity

Antibody Response: Not Reported

T cell Response (ELISpot): Not Reported

Reference

Pfizer Slide Deck Phase 1b result

Pfizer Press Release

Clinicaltrial.gov

Comments

Popular posts from this blog

Carbohydrate Metabolism: MCQs and answers on Glycolysis & Gluconeogenesis

                                      MCQ on Glycolysis & Gluconeogenesis 1) Which of the following enzyme is not involved in galactose metabolism? a) Glucokinase b) Galactokinase c) Galactose-1-Phosphate Uridyl transferase d) UDP-Galactose 4- epimerase 2) Which of the following enzyme is defective in galactosemia (type I) - a fatal genetic disorder in infants? a) Glucokinase b) Galactokinase c) Galactose-1-Phosphate Uridyl transferase d) UDP-Galactose 4- epimerase 3) In the liver, the accumulation of which of the following metabolite attenuates the inhibitory of ATP on phosphofructokinase? a) Glucose-6-Phosphate b) Citrate c) Fructose-1,6-Bisphosphate d) Fructose-2,6-Bisphosphate 4) Mutation in which of the following enzymes leads to a glycogen storage disease known as "Tarui’s disease"? a) Glucokinase b) Phosphofructokinase c) Phosphoglucomutase d) Pyruvate Kinase 5) E...

MCQs and Answers on cultivation (culture/incubation), Isolation and Identification of microorganisms: Medical Microbiology

40 plus questions - Multiple Choice Questions on Classification, Culture, and Identification of the microorganisms 1. Which of the following microorganism has the cocci cell shapes and sizes arranged usually in tetrad structures? a)  Streptococcus pneumoniae b)  Staphylococcus aureus c)  Chlamydia trachomatis d)  Neisseria meningitidis 2. What are the different growth morphology and cell structures used for the classification of fungi? Select all the correct answers: a) Yeast b) Mold c) Mycelia d) Protozoa 3. Which of the following media is formulated with additional nutrients to support the growth of fastidious or nutritionally demanding bacteria that may not grow well on basic media? a) Differential media b) Enriched media c) Nutrient agar (media) d) Selective media 4. Which of the following metabolic characteristic is a distinguishing characteristic and identification of colonies of  E. coli ? a) Hydrogen sulfide formation b) Indole Formation c) Lactose fe...

MCQs on Bacterial Pathogenesis: Medical Microbiology

Key aspects of Bacterial pathogenesis/ General steps in bacterial pathogenesis Adherence and Colonization  Invasion Immune Evasion Toxin Production Nutrient Acquisition Host Cell Manipulation Inflammation and Tissue Damage                         Multiple Choice Questions on Bacterial Pathogenesis       Figure 1: Phagocyte activity and possible outcomes of phagocyte-bacterial interactions                                     (Source/Reference: Bailey & Scott’s Diagnostic  Microbiology) 1) Which of the following microorganism is the major inhabitant of the human skin? a) Escherichia coli b) Staphylococcus epidermidis c) Staphylococcus aureus d) Streptococcus pyogenes 2) Select all the medically important bacteria which are frequently isolated pathogen  human infections? a) Enteric ba...